MEDCAC Q&A with Louis Jacques, ADVI Chief Medical Officer

On May 16, the Centers for Medicare and Medicaid Services (CMS) released a tracking sheet for a National Coverage Analysis (NCA) for Chimeric Antigen Receptor (CAR) T-cell therapies. CMS simultaneously announced an August 22 public meeting of its Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) advisory panel meeting on CAR-T therapies.

[/el-text]

Read full article here